Principal investigator

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO

Retrieved on: 
Tuesday, April 2, 2024
Lung cancer, Internal medicine, Stanford Cancer Institute, Entrepreneurship, Princeton University, Immunotherapy, Oncology, International Association, Research, Cancer, Doctor of Philosophy, MD, Mesothelioma, CD24, MacArthur Fellows Program, Johns Hopkins University, Principal investigator, SAB, Division, Stanford University, CSO, Thymoma, Pharmaceutical industry

“We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.

Key Points: 
  • “We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.
  • By leveraging universal pathways, OncoC4 has the potential to change the treatment paradigm for many common and aggressive cancers with high unmet needs.
  • Currently she serves as Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology.
  • She is the Principal Investigator on numerous clinical trials and has held advisory board roles with multiple international pharmaceutical companies.

The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, ChromeOS, FJD, MBE, Growth, Environment, Patient, Pi, Cancer, EMA, MD, FRCPC, START, PDX, Clinical trial, Safety, Multimedia, Principal investigator, FDA, Physician, Pharmaceutical industry

The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.

Key Points: 
  • The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.
  • Slack, a respected leader in the clinical research industry, brings nearly 20 years of experience to grow START's mission of revolutionizing cancer clinical research.
  • With a global network spanning eight locations, including START San Antonio, START Midwest, START Mountain Region, START Madrid (FJD and CIOCC), START Barcelona, START Dublin, and START Lisbon, START is at the forefront of advancing cancer research.
  • Co-founders of The START Center for Cancer Research, Amita Patnaik, MD, FRCPC, and Kyriakos P. Papadopoulos, MD, will continue their pivotal roles as Co-directors of Clinical Research at START San Antonio.

Pacing Toward Progress: Dr. Daniel Corcos' Trailblazing Research Reveals Exercise's Potential to Slow Parkinson's Disease Progression

Retrieved on: 
Monday, April 8, 2024
Exercise, Disease, PD, Alzheimer's disease, Risk, Patient, Heart rate, State, Observation, Parkinson's disease, Woman, Cognition, Principal investigator, Urban, Neurodegenerative disease, Pharmaceutical industry

As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.

Key Points: 
  • As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.
  • Moreover, men are 1.5 times more likely to develop Parkinson's disease than women.
  • Three recent studies, suggests that endurance exercise may offer a significant breakthrough in Parkinson's treatment in that the suggest that exercising at 80% of maximum heart rate may slow disease progression.
  • Dr. Corcos underscores the indispensable role of aerobic exercise in Parkinson's treatment, citing evidence suggesting its potential to slow disease progression.

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Monday, March 18, 2024
Proton, Magnetic resonance imaging, Patient, Biomarker, MASH, Trial of the century, MBA, Doctor of Philosophy, Principal investigator, Therapy, Safety, Pharmacokinetics, Liver, Magnetic resonance, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.

Key Points: 
  • The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison
    SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • Screening of subjects has begun at clinical study sites across the U.S.
    “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile.
  • We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH.
  • The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos Therapeutics.

Dr. Ava Shamban Joins MedSpa Partners

Retrieved on: 
Wednesday, March 13, 2024
Vanity Fair, Beauty, Patient, Rest, Dermatology, Publication, Good Morning America, Women's health, Principal investigator, AVA, MSP, Extreme Makeover, Health, Television, Medical device

TORONTO, March 13, 2024 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Ava Shamban and her team at Ava MD to its top-tier North American medical aesthetics platform.

Key Points: 
  • TORONTO, March 13, 2024 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Ava Shamban and her team at Ava MD to its top-tier North American medical aesthetics platform.
  • Speaking on her reasons for joining MedSpa Partners, Dr. Shamban shared, "Like many of my colleagues, I was approached by numerous groups looking to acquire my practices.
  • MSP CEO Dominic Mazzone commented, "While Los Angeles can be associated with some of the more extreme approaches to cosmetic medicine, Ava Shamban is an icon for the kind of natural, individualized, and responsible medical aesthetics that MedSpa Partners promotes.
  • We couldn't be more excited to welcome Dr. Shamban and the exceptional team at Ava MD to MedSpa Partners."

Alcanza Clinical Research Appoints James Clark, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
ChromeOS, Internal medicine, Health equity, Research, Acquisition, University, Principal investigator, Multimedia, Medical device

LAKE MARY, Fla., March 12, 2024 /PRNewswire/ -- Alcanza Clinical Research , a mission-focused investigator site network, has appointed James Clark, M.D., as its first-ever Chief Medical Officer, marking a milestone in Alcanza's growth journey as it expands its network size and patient reach.

Key Points: 
  • LAKE MARY, Fla., March 12, 2024 /PRNewswire/ -- Alcanza Clinical Research , a mission-focused investigator site network, has appointed James Clark, M.D., as its first-ever Chief Medical Officer, marking a milestone in Alcanza's growth journey as it expands its network size and patient reach.
  • "We are thrilled to have Dr. Clark join the Alcanza senior leadership team as our Chief Medical Officer," said Bob Kinard, President and CEO, Alcanza.
  • "Now as Chief Medical Officer, I look forward to making a bigger impact toward our collective commitment to provide inclusive clinical research and accelerate the development of new therapies by reducing barriers to clinical research participation for all."
  • Alcanza is an integrated network of research facilities dedicated to reducing barriers to clinical research participation, especially in underrepresented patient populations.

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

Retrieved on: 
Monday, March 4, 2024
Bangladesh Technical Education Board, Natural history, Gene, Nationwide, NIH, ATPase, FDA, Fortress Biotech, Food, Cerebrospinal fluid, Hospital, Principal investigator, Gene therapy, Human, Research institute, Therapy, Menkes disease, Patient, X-linked recessive inheritance, Cyprium, CSF, Clinical trial, Pediatrics, Fortification, Male, Genetics, Mutation, Spinal muscular atrophy, Copper, NDA, Orphan, AAV, DSM-IV codes, Research, Mouse, Pharmaceutical industry

MIAMI, March 04, 2024 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), today announced that the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) has awarded a three-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital and Principal Investigator, Stephen G. Kaler, M.D., M.P.H., to fund completion of preclinical studies, manufacturing and preparation of an Investigational New Drug Application for a first-in-human clinical trial to advance adeno-associated virus (“AAV”)-ATP7A gene therapy, also known as AAV-ATP7A, for the treatment of Menkes disease.

Key Points: 
  • Often lethal if untreated, Menkes disease is an X-linked recessive disorder of copper metabolism caused by mutations in ATP7A, an evolutionarily conserved copper-transporting ATPase.
  • “By combining CUTX-101 with working copies of ATP7A delivered by AAV, we hope to enhance clinical outcomes in Menkes disease, a fatal rare pediatric disease.
  • Preclinical studies have demonstrated a synergistic effect of AAV-ATP7A and CUTX-101 in a reliable mouse model of Menkes disease.
  • In early studies, cerebrospinal fluid (“CSF”)-directed AAV gene therapy rescued 22-53% of mice with a mutation in the human Menkes disease homolog (mottled-brindled) when combined with CSF or subcutaneous copper.

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Retrieved on: 
Thursday, February 22, 2024
Nervous system, POC, AMIX, Principal, Collateral damage, Pain, Principal investigator, Patient, Disease, Trial of the century, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed selection of Principal Investigators for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. Additionally, the Principal Investigators have successfully completed training for the PoC study.

Key Points: 
  • Additionally, the Principal Investigators have successfully completed training for the PoC study.
  • “We are building important momentum with the advancement of our PoC human clinical study.
  • We worked diligently to identify and secure our Principal Investigators for the study and have completed the training for this first study ever to evaluate RF ablation in a transvascular approach.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the study.

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Retrieved on: 
Wednesday, February 21, 2024
SAN, Sarcoidosis, Scar, Small RNA, Pi, ATyr Pharma, FDA, Inflammation, Food, Scleroderma, Risk, Myelocyte, Health, Safety, Principal investigator, Expanded access, Neuropilin, Systemic scleroderma, ILD, OLE, Patient, Fibrosis, Clinical trial, EAP, Pharmaceutical industry

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced plans to initiate an Individual Patient Expanded Access Program (EAP) for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis. The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.

Key Points: 
  • Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis.
  • Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.
  • The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.
  • “We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT™ clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, BMD, Exercise, Principal investigator, Network, Myopathy, Edgewise, Conference, Muscular Dystrophy Association, University, Therapy, ARCH, Associate professor, University of Florida, Poster, Trade, Convention, MDA, Physiology, Episcopal conference, University of Copenhagen

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.
  • The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024.
  • Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET.
  • The Edgewise presentation and posters will be available on the Edgewise website when they are presented.